Inhibikase Therapeutics, Inc. (IKT) Stock Forecast
IKT analyst forecast
as of October 18, 2026- Analyst consensus
- Strong buy 4.70 / 5 from 10 analysts
- Price target
- $5.55 average of analyst targets
- Upside to target
- +236.4% from the latest close
- Next earnings
- November 13, 2026 EPS estimate $-0.11
- 52-week range
- $1.41 – $2.52
IKT analyst ratings
10 analystsNumber of analysts at each rating.
IKT price target
The average of analyst 12-month price targets compared with the latest close and the 52-week range.
IKT earnings per share estimates
| Period | Average | Low | High | Year ago | Growth | Analysts |
|---|---|---|---|---|---|---|
| Current quarter (Sep '26) | −$0.12 | −$0.16 | −$0.11 | — | — | 4 |
| Current fiscal year (2026) | −$0.40 | −$0.45 | −$0.33 | −$0.49 | +0.7% | 5 |
| Next fiscal year (2027) | −$0.42 | −$0.48 | −$0.37 | −$0.40 | −5.0% | 5 |
Consensus EPS estimates; growth compares the average estimate with the year-ago EPS.
IKT revenue estimates
| Period | Average | Low | High | Growth | Analysts |
|---|---|---|---|---|---|
| Current quarter (Sep '26) | $0 | $0 | $0 | 0.0% | 8 |
| Current fiscal year (2026) | $187,500 | $0 | $1.5M | 0.0% | 8 |
| Next fiscal year (2027) | $250,000 | $0 | $2.0M | +33.3% | 8 |
IKT EPS: reported and forecast
Fiscal years; "E" marks estimates, the line shows the range from the lowest to the highest estimate.
IKT revenue: reported and forecast
IKT EPS estimate revisions
| Period | 90 days ago | 60 days ago | 30 days ago | 7 days ago | Now | Change (90 d) | Revisions (30 d) |
|---|---|---|---|---|---|---|---|
| Current quarter (Sep '26) | −$0.09 | −$0.10 | −$0.11 | −$0.11 | −$0.12 | +38.9% | 0 up · 1 down |
| Current fiscal year (2026) | −$0.37 | −$0.44 | −$0.45 | −$0.45 | −$0.40 | +8.1% | 0 up · 1 down |
| Next fiscal year (2027) | −$0.38 | −$0.42 | −$0.43 | −$0.43 | −$0.42 | +10.5% | 0 up · 1 down |
How the consensus EPS estimate changed over the last 90 days, and how many analysts raised or lowered it in the last 30 days.
IKT earnings surprises
Reported EPS vs the consensus estimate for the last 12 quarters; IKT beat in 6 of 12.
What analysts expect from IKT
10 analysts cover Inhibikase Therapeutics; their consensus rating is strong buy (4.70 on a 1–5 scale, where 5 is a strong buy). The average price target is $5.55, 236.4% above the latest close of $1.65. Analysts expect earnings of −$0.40 per share for 2026, +0.7% from a year earlier. For 2027 the average estimate is −$0.42 per share on revenue of $0.2 million. Inhibikase Therapeutics beat the EPS estimate in 6 of the last 12 quarters.
Related: IKT income statement, IKT key metrics, IKT chart. See the IKT stock overview for the latest quote and news.
IKT forecast FAQ
What is Inhibikase Therapeutics's price target?
The average analyst price target for Inhibikase Therapeutics is $5.55, 236.4% above the latest close of $1.65.
Is Inhibikase Therapeutics a buy, hold or sell?
Of 10 analysts covering Inhibikase Therapeutics, 8 rate it a strong buy, 1 a buy, 1 a hold, 0 a sell and 0 a strong sell, a consensus of strong buy. Ratings are opinions, not a recommendation from Quotelinks.
What is Inhibikase Therapeutics's EPS forecast?
Analysts forecast −$0.40 per share for 2026 (range −$0.45 to −$0.33); for 2027 the estimate is −$0.42.
What is Inhibikase Therapeutics's revenue forecast?
The average revenue estimate for 2026 is $0.2 million, growth of 0.0%; for 2027 it is $0.2 million.
When does Inhibikase Therapeutics report earnings?
Inhibikase Therapeutics is expected to report results for the quarter ending September 30, 2026 on November 13, 2026 after the market closes; the EPS estimate is $-0.11.
Does Inhibikase Therapeutics usually beat earnings estimates?
Inhibikase Therapeutics reported EPS at or above the analyst estimate in 6 of the last 12 quarters.